Does NIVOLUMAB Cause Immune-mediated hepatitis? 640 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 640 reports of Immune-mediated hepatitis have been filed in association with NIVOLUMAB (OPDIVO). This represents 0.7% of all adverse event reports for NIVOLUMAB.
640
Reports of Immune-mediated hepatitis with NIVOLUMAB
0.7%
of all NIVOLUMAB reports
94
Deaths
360
Hospitalizations
How Dangerous Is Immune-mediated hepatitis From NIVOLUMAB?
Of the 640 reports, 94 (14.7%) resulted in death, 360 (56.3%) required hospitalization, and 95 (14.8%) were considered life-threatening.
Is Immune-mediated hepatitis Listed in the Official Label?
Yes, Immune-mediated hepatitis is listed as a known adverse reaction in the official FDA drug label for NIVOLUMAB.
What Other Side Effects Does NIVOLUMAB Cause?
Death (11,216)
Malignant neoplasm progression (9,363)
Off label use (5,208)
Diarrhoea (4,692)
Fatigue (3,709)
Pyrexia (3,454)
Intentional product use issue (3,297)
Rash (2,816)
Nausea (2,805)
Decreased appetite (2,619)
What Other Drugs Cause Immune-mediated hepatitis?
PEMBROLIZUMAB (549)
IPILIMUMAB (443)
CARBOPLATIN (213)
PACLITAXEL (167)
ATEZOLIZUMAB (142)
BEVACIZUMAB (108)
DURVALUMAB (90)
LENVATINIB (86)
PEMETREXED (86)
TREMELIMUMAB (51)
Which NIVOLUMAB Alternatives Have Lower Immune-mediated hepatitis Risk?
NIVOLUMAB vs NIVOLUMAB\RELATLIMAB-RMBW
NIVOLUMAB vs NIZATIDINE
NIVOLUMAB vs NOMEGESTROL
NIVOLUMAB vs NORDAZEPAM
NIVOLUMAB vs NOREPINEPHRINE